Dyadic International, Inc. Share Price Other OTC
Equities
US26745T1016
Biotechnology & Medical Research
Sales 2024 * | 4.2M 334M | Sales 2025 * | 6.1M 486M | Capitalization | 43.56M 3.47B |
---|---|---|---|---|---|
Net income 2024 * | -22M -1.75B | Net income 2025 * | -31M -2.47B | EV / Sales 2024 * | 10.4 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.14 x |
P/E ratio 2024 * |
-2.26
x | P/E ratio 2025 * |
-1.66
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.91% |
Latest transcript on Dyadic International, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 31/12/78 |
Ping Rawson
DFI | Director of Finance/CFO | 48 | 31/05/16 |
Joseph Hazelton
COO | Chief Operating Officer | 48 | 08/11/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 31/12/78 |
Jack Kaye
BRD | Director/Board Member | 80 | 30/04/15 |
Michael Tarnok
BRD | Director/Board Member | 69 | 11/06/14 |
1st Jan change | Capi. | |
---|---|---|
+2.02% | 42.75B | |
+47.70% | 41.61B | |
+12.38% | 41.34B | |
-8.83% | 26.59B | |
+6.47% | 25.49B | |
-22.86% | 18.12B | |
+30.51% | 12.24B | |
-2.05% | 11.76B | |
+8.60% | 11B |